News brief­ing: Atom­wise part­ners with Is­raeli in­cu­ba­tor; Bay­er col­lab­o­rates with Ve­r­a­cyte in thy­roid can­cer

AI play­er Atom­wise has teamed up with the Is­raeli-based in­cu­ba­tor Fu­tuRx to launch a com­pa­ny that will use its plat­form tech to tar­get a new drug for im­muno-on­col­o­gy.

A2i Ther­a­peu­tics will tap the Is­raeli In­no­va­tion Au­thor­i­ty, the Fu­tuRx in­vestors, and in-kind re­sources and sup­port pro­vid­ed by Atom­wise for the help it needs set­ting out.

“Fu­tuRx is ex­cit­ed to launch a new bio con­ver­gence com­pa­ny joint­ly with a world leader in AI-based drug dis­cov­ery,” said Kin­neret Sav­itzky, the CEO of Fu­tuRx. — John Car­roll

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER